Kiyean Nam

This inventor holds 11 USPTO granted patents and 7 published patent applications, plus 1 CIPO patent and 7 EPO patents. Top assignees: Qurient Co., Ltd., Lead Discovery Center Gmbh, Qurient Co., Ltd.. Active years: 2015-2026.

USPTO Granted Patents = 11 (Patent Applications = 7)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 10)

EPO Patents = 7 (Patent Applications = 14)

Average Co-Inventor Count = 6.9

ph-index = 1

Forward Citations = 29(Granted Patents)

Location History:

Seoul, KR (2015)
Gyeonggi-do, KR (2021 - 2024)

Company Filing History:

Lead Discovery Center Gmbh

Institut Pasteur Korea

patents

where one patent can have more than one assignee

Years Active: 2015-2026

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12698288 - Compounds having cyclin-dependent kinase(CDK)-inhibitory function (2026-08-04),

2. 12653787 - Pharmaceutical oral dosage form of Q203 (2026-06-16),

3. 12606561 - Substituted pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors (2026-04-21),

4. 12582598 - Topical anti-inflammatory pharmaceutical composition comprising Zileuton (2026-03-24),

5. 12410165 - Different forms of 6-chloro-2-ethyl-N-(4-(4-(4-(trifluoromethoxy)phenyl)piperidine-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide (2025-09-09),

6. 12162858 - Quinoline derivatives as inhibitors of AXL/MER RTK and CSF1R (2024-12-10),

7. 11945822 - Pyrazolo-triazine and/or pyrazolo-pxrimidine derivatives as selective inhibitor of cyclin dependent kinase (2024-04-02),

8. 11858937 - Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors (2024-01-02),

9. 11447486 - 2-amino-benzimidazole derivatives and their use as 5-lipoxygenase and/or prostaglandin E synthase inhibitors (2022-09-20),

10. 10934274 - Quinoline derivatives as TAM RTK inhibitors (2021-03-02),

11. 9029389 - Anti-inflammation compounds (2015-05-12),

Title: Kiyean Nam: Innovator in Pharmaceutical Compounds

Introduction

Kiyean Nam is a prominent inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of pharmaceuticals, holding a total of seven patents. His work primarily focuses on innovative compounds that have potential therapeutic applications.

Latest Patents

Among his latest patents, Kiyean Nam has developed different forms of the compound 6-chloro-2-ethyl-N-(4-(4-(4-(trifluoromethoxy)phenyl)piperidine-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide. This invention relates to various forms of the compound, methods of making these forms, and mono-acid addition salts thereof. Additionally, he has patented quinoline derivatives that serve as inhibitors for Axl/Mer RTK and CSF1R. These compounds are particularly relevant for treating hyperproliferative disorders, including various types of cancer and inflammatory diseases.

Career Highlights

Kiyean Nam has worked with notable companies in the pharmaceutical sector, including Qurient Co., Ltd. and Lead Discovery Center GmbH. His experience in these organizations has allowed him to advance his research and development efforts significantly.

Collaborations

Kiyean has collaborated with several professionals in his field, including Jaeseung Kim and Yeejin Jeon. These collaborations have contributed to the success of his innovative projects and patents.

Conclusion

Kiyean Nam is a distinguished inventor whose work in pharmaceutical compounds has the potential to impact various medical fields. His innovative patents and collaborations highlight his commitment to advancing healthcare solutions.